Tirzepatide 40 mg
This lot was tested by Janoshik on 20 Jan 2026. Purity was measured by RP-HPLC, 220 nm. The signed report is reproduced below; the figures on this page are transcribed from it.
- Batch number
- -EGB-0126-TR40
- Compound
- Tirzepatide 40 mg
- Tested
- 20 Jan 2026
- Laboratory
- Janoshik
- Report reference
- Janoshik task #100378, key 5P8TRAFCXWMW
- Purity
- 99.77 % (RP-HPLC, 220 nm)
- Net peptide content
- 42.2 mg
- Purity, RP-HPLC, 220 nm
- 99.77 %
- Net peptide content
- 42.2 mg
- Tested
- 20 Jan 2026
- Laboratory
- Janoshik
What this certificate shows
Purity 99.77 %. Reversed-phase HPLC separates the contents of the vial by how they interact with the column, and a UV detector measures each peak. 99.77 % of the detected material in lot -EGB-0126-TR40 is the target peptide, Tirzepatide 40 mg; the remaining 0.23 % is made up of closely related sequences and synthesis by-products. Purity describes what the peptide portion is, not how much powder is in the vial.
Net peptide content 42.2 mg. The amount of peptide actually present in the tested vial, as opposed to the labelled size of 40 mg. Lyophilised powder also contains counter-ions and residual moisture, so net content is the figure to use when calculating concentrations.
How each figure is measured, and the limits a lot must meet before release, are set out in our testing methods. For in-vitro laboratory research only.